14 C Health & Fitness / The Economic Times
Viatris has revealed that the FDA has restricted imports of 11 products made at its Indian facility after an inspection found violations of federal requirements. The affected products will not be accepted in the U.S. until the issue is resolved. The site makes oral finished doses like tablets and capsules. Viatris is working on corrective actions.
India is set to strengthen its pharmaceutical and healthcare sectors. The government is launching production-linked incentives and building bulk drug parks. These initiatives aim to boost domestic drug production. The government is also promoting research and innovation in pharmaceuticals and medical technology. Support for traditional medicine (AYUSH) is also increasing.
India's first diabetes biobank has been established in Chennai by ICMR and MDRF. The biobank houses samples from two major studies, including the ICMR-INDIAB study, and will facilitate research on diabetes variations and personalized treatments. It aims to improve understanding, diagnosis, and management of diabetes in India.
Sun Pharmaceutical Industries Ltd has been penalized by the Ministry of Corporate Affairs for non-disclosure and failure to obtain necessary board and shareholder approvals for certain related party transactions in the past. The penalties apply to certain past and present directors and officials. The issues relate to transactions from financial years 2014-15 to 2018-19.
Glenmark Pharmaceuticals Inc., USA launched a generic version of Travatan Z, a glaucoma treatment, called Travoprost ophthalmic solution (0.004%). This bioequivalent solution expands Glenmark's ophthalmic product line and addresses market demands. Travatan Z generated approximately $66.2 million in sales over the past year.